Last reviewed · How we verify
Methylthioninium — Competitive Intelligence Brief
phase 3
Microtubule-associated protein tau, Amine oxidase [flavin-containing] A, Amine oxidase [flavin-containing] B
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Methylthioninium (Methylthioninium) — Shandong Cancer Hospital and Institute.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Methylthioninium TARGET | Methylthioninium | Shandong Cancer Hospital and Institute | phase 3 | Microtubule-associated protein tau, Amine oxidase [flavin-containing] A, Amine oxidase [flavin-containing] B |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Methylthioninium CI watch — RSS
- Methylthioninium CI watch — Atom
- Methylthioninium CI watch — JSON
- Methylthioninium alone — RSS
Cite this brief
Drug Landscape (2026). Methylthioninium — Competitive Intelligence Brief. https://druglandscape.com/ci/methylthioninium. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing